|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study implies an association of breast cancer risk with the p53 polymorphism Arg72Pro, but not with p73 G4A.
|
14634508 |
2003 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We pooled data from four breast cancer cohorts within the Breast Cancer Association Consortium for which both TP53 R72P and MDM2 SNP309 were genotyped and follow-up was available (n = 3,749).
|
20021639 |
2009 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, we investigated whether MDM2-SNP309 is associated with p53 R72P genetic polymorphism for the risk of breast cancer development in Asian Taiwanese, which has not been well-studied in this regard.
|
21479369 |
2011 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
|
19707196 |
2009 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results suggest that TP53 c.215G>C, p. (Arg72Pro) polymorphism may be considered as a genetic marker for predisposition to BC in Moroccan population.
|
29949804 |
2018 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Allele 399Gln (OR 1.57; 95% CI 1.05-2.35), Arg399Gln of gene XRCC1 heterozygous genotype (OR 2.77; 95% CI 1.60-4.80), the combination of Arg399Gln/Arg72Pro of genes XRCC1/TP53 heterozygous genotype (OR 3.98; 95% CI 1.57-10.09), Arg399Gln/T309G of genes XRCC1/MDM2 (OR 3.0; 95% CI 1.18-7.56), as well as Arg399Gln/Arg72Pro/T309G of genes XRCC1/TP53/MDM2 (OR 6.40; 95% CI 1.18-34.63) were associated with BC in Kyrgyz women.
|
29132330 |
2017 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
To investigate the role of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms in breast cancer patients treated with 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy.
|
20638924 |
2010 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Role of GSTM1 (Null/Present), GSTP1 (Ile105Val) and P53 (Arg72Pro) genetic polymorphisms and the risk of breast cancer: a case control study from South India.
|
17696741 |
2008 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
These observations suggested that neither the Ins16bp or Arg72Pro polymorphisms considered separately, nor any related haplotype, were associated with breast cancer risk in BRCA-mutation negative familial cases.
|
18640791 |
2008 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Interestingly, we observed a combinational effect between MDM4 rs4245739 and P53 Arg72Pro variants in attenuating breast cancer risk, highlighting the importance of the P53 tumor suppressor pathway genes during malignant transformation.
|
23793604 |
2013 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our finding suggests that TP53 (Arg72Pro) polymorphism may play a significant role as risk factor for breast cancer in north Indian breast cancer patients.
|
26553387 |
2016 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we investigated the effect on breast cancer survival of germline variation in these genes in 925 Finnish breast cancer patients and further analyzed five single nucleotide polymorphisms (SNPs) in PRKAG2 (rs1029946, rs4726050, rs6464153, rs7789699) and PPP2R2B (rs10477313) for 10-year survival in breast cancer patients, interaction with TP53 R72P and MDM2-SNP309, outcome after specific adjuvant therapy and correlation to tumor characteristics in 4,701 invasive cases from four data sets.
|
23034890 |
2013 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy.
|
18058229 |
2008 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, the results obtained from the combination of SNPs 344T>A of MDM2 and 72 Arg/Pro of p53, do not support the hypothesis of the prominent role of common p53 and MDM2 variations in the genetic mechanisms of chemotherapy resistance in breast cancer.
|
27569097 |
2016 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The present study was undertaken to investigate the association of p53 Arg72Pro, Ins16bp and G13964C polymorphisms and their haplotypes with breast cancer risk in Tunisian women.
|
20233677 |
2010 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The findings of our case-control study and meta-analysis suggest a significant association between p53 Arg72Pro polymorphism and an increased risk of breast cancer in Indian population.
|
30065615 |
2018 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The results of present study indicated that among the five TP53 polymorphisms investigated, the p.R72P polymorphism, and the RP-A1A1 and RP-GG genotype combination contribute to breast cancer susceptibility in North Indians.
|
25169539 |
2014 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.
|
23716179 |
2013 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Allele distribution of the R72P missense mutation between ethnically diverse Jewish breast cancer cases and average risk controls showed significant differences: among non-Ashkenazi breast cancer cases, 62.5%, 33.3% and 4.2% were homozygous, heterozygous and homozygous for the Arg72, Arg72Pro and the Pro72 polymorphism, respectively, whereas for controls, the distribution was 22.4%, 65.4% and 12.2%, respectively (P=0.00052), and among Ashkenazi breast cancer cases, allele distribution was 68.5%, 29.6% and 1.9%, whereas for controls, the distribution was 50%, 40% and 10%, respectively (P=0.0125).
|
15756275 |
2005 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The TP53 polymorphisms Arg72Pro (Ex4+199 G>C) and Ins16 (IVS3+24 ins16) have been proposed to modify risk of breast cancer associated with germline BRCA1 and BRCA2 mutations.
|
18402691 |
2008 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
The P53 gene codon 72 Arg/Pro and Her2 gene Ile655Val polymorphisms were not associated with the risk of breast cancer in Turkish women.
|
20380571 |
2010 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study investigates the role of 3 nonsynonymous SNPs in the DNA repair genes XRCC1 (R399Q), RAD51 (G135C) and TP53 (Arg72Pro) in breast cancer in Serbian women.
|
26954070 |
2016 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
We evaluated whether three well-characterized TP53 variants -- Ex4 + 119 C > G (rs#1042522, Arg72Pro), IVS6 + 62 A > G (rs#1625895), and an IVS3 16 bp insertion/ deletion (INDEL; rs#17878362) -- were associated with breast cancer risk in a population-based case-control study.
|
17624591 |
2008 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Neither combined nor homozygous/heterozygous MDM-2 SNP309G was associated with total, premenopausal, or postmenopausal breast cancer risk; however, MDM-2 SNP309G, along with p53 Arg72Pro heterozygous variant, showed a significant protective association with premenopausal breast cancer risk (odds ratio [95% confidence interval]: 0.18 [0.02-1.20], p value; 0.041 for homozygous + heterozygous MDM-2 SNP309G).
|
17719241 |
2008 |
|
rs878854066
|
|
Breast Carcinoma
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genetic data revealed that the p53 Arg72Pro genotype was found to be greatly associated with breast cancer risk (p<0.001), as well as tumor site (p=0.046).
|
25750340 |
2015 |